NCT02985957 2025-12-22
CheckMate 650
Bristol-Myers Squibb
Phase 2 Completed
Clinical Trials
9 trialsNCT01377389 2023-09-29
Ipilimumab + Androgen Depravation Therapy in Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT02601014 2022-02-03
STARVE-PC
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT02506114 2021-11-24
Neoadjuvant PROSTVAC-VF With or Without Ipilimumab for Prostate Cancer
University of California, San Francisco
Phase 2 Terminated
NCT01804465 2021-08-18
Sipuleucel-T With Immediate vs. Delayed Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Blockade for Prostate Cancer
University of California, San Francisco
Phase 2 Completed
NCT02279862 2019-08-28
Safety and Efficacy Study of Ipilimumab 3 mg/kg Versus Ipilimumab 10 mg/kg in Subjects With Metastatic Castration Resistant Prostate Cancer Who Are Chemotherapy Naive
Bristol-Myers Squibb
Phase 2 Completed
NCT00861614 2016-09-30
Study of Immunotherapy to Treat Advanced Prostate Cancer
Bristol-Myers Squibb
Phase 3 Completed
NCT01057810 2016-08-18
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Bristol-Myers Squibb
Phase 3 Completed
NCT00323882 2014-08-28
Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer
Bristol-Myers Squibb
Phase 1/2 Completed